Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Tom1 CRISPR/Cas9 KO Plasmid (m): sc-423467
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- Tom1 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the Tom1 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: Tom1 Antibody (H-5): sc-514430
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Tom1 CRISPR/Cas9 KO Plasmid (m) | sc-423467 | 20 µg | $397.00 |
Overview
Tom1 (target of Myb1) encodes an endosomal adaptor protein that couples ubiquitinated cargo to ESCRT-associated trafficking machinery, contributing to endosome maturation and lysosomal sorting. Through interactions with clathrin- and ESCRT-related components, TOM1 helps regulate receptor turnover, membrane protein homeostasis, and signaling attenuation following endocytosis. These processes intersect with autophagy–lysosome function and innate immune signaling, making Tom1 relevant for studying how vesicular transport modulates inflammation and cellular stress responses. Dysregulated endosomal sorting and ubiquitin-dependent trafficking are frequently linked to neuroinflammatory and neurodegenerative phenotypes as well as immune dysregulation in mouse models.
Tom1 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Tom1 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Tom1 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Tom1 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish Tom1 protein expression.
This CRISPR knockout system enables efficient generation of Tom1-deficient cell models for investigation of Tom1 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Tom1 exon(s) critical for Tom1 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Tom1 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by Tom1 CRISPR/Cas9 KO Plasmid (m) and Tom1 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Tom1 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by Tom1 HDR Plasmid (m) and Tom1 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Tom1 homology arms to support homology-directed repair at defined Tom1 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.